01

Mar2023
INESSS has published its updated fee schedule for its scientific evaluation of drugs, stable blood products and technologies in the February 18, 2023 Gazette du Québec. Fees for all submission types have increased 6.44% as of January 1, 2023, bringing fees to: $63,791 for a new ... Read More

20

Dec2022
The Institut national d’excellence en Santé et en services sociaux (INESSS) has recently updated the Guidance Document for Submitting a Request to INESSS and affiliate documents. This document consolidates updates previously communicated through manufacturer notices and replaces the 2018 version of the guidelines.  ... Read More

03

Dec2020
INESSS has announced the implementation of a waiting list for requests for scientific evaluation received by INESSS as of November 16, 2020. PDCI has outlined below the key highlights from the most recent newsletter. The Institut national d’excellence en santé et en services sociaux (INESSS) has reported a ... Read More

08

Aug2019
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website. CADTH has three new consultations ... Read More

12

Nov2018
INESSS has launched a modernized website that is more user-friendly and provides greater transparency. Some of the highlighted new features includes: Enhanced search engine that allows broader searches throughout the full website and that offers additional Advance Search filters. New Social Services, Drugs and Health Services sections which provide new ... Read More

28

Jun2018
Health Canada, CADTH, and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) have officially launched efforts to align regulatory and health technology assessment (HTA) drug reviews for eligible submissions, effective immediately. Background The new process stems from Health Canada and HTAs recognizing the need for greater coordination of the ... Read More

30

Apr2018
On April 27, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers advising that their submission guide document, submission checklists and various forms and letter templates have been updated effective immediately. For more information, please consult the following link or the ... Read More

05

Apr2018
On April 4, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the evaluation process. Pre-NOC Evaluations Manufacturers can submit an application for registration to INESSS for a new innovative drug product, a new biosimilar drug product, a new product ... Read More

23

Feb2018
On February 21, 2018, the Gazette officielle du Québec announced that draft regulations, relating to the implementation of fees for manufacturers submitting a scientific evaluation to the Institut national d’excellence en santé et en services sociaux (INESSS), have been submitted to the government of Québec for approval. The fees will vary ... Read More

30

Jan2018
On January 29, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers. This notice is a supplement to the information published on August 18, 2017 regarding changes of an administrative nature. Requests for withdrawals from the Liste des médicaments and the Liste des ... Read More